Brain proton magnetic resonance spectroscopy in Alzheimer disease: changes after treatment with xanomeline
1. 当前求助状态已完结, 请及时下载应助文件
2. 系统将在 2026-07-01 16:27:54 删除文件
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接: https://pubmed.ncbi.nlm.nih.gov/11790638
其他信息:
PMID: 11790638
作者: Blaise deB Frederick; Andrew Satlin; Lawrence L Wald; John Hennen; Neil Bodick; ...
摘要: Patients with mild-to-moderate Alzheimer disease received transdermal xanomeline, an M1-selective cholinergic agonist, or placebo for 4 months. Clinical assessments and proton magnetic resonance spectroscopic imaging examinations were carried out at baseline, and after 8 and 16 weeks of treatment. There was a positive correlation between change from baseline in parietal lobe gray-matter cytosolic choline, expressed in terms of choline/creatine resonance ratios, and cognitive performance as measu...
